Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...

Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The study screened over 6,000 patients ...

Background/objectives: Multiple systemic treatments are available for metastatic castration-resistant prostate cancer (mCRPC), with unclear safety profiles. This study seeks to describe the safety ...

Artificial intelligence (AI) is reshaping the landscape of men's health by enhancing diagnostic accuracy, personalizing treatment strategies, and improving clinical efficiency. This narrative review ...

At the 2025 UCSF-UCLA PSMA Conference, Vadim Koshkin discusses radioligand therapies for bladder cancer. He highlights that gallium-FAP-2286 imaging shows bladder cancer has the highest FAP uptake ...

At the 2025 UCSF-UCLA PSMA Conference, Thomas Hope challenges using PSMA PET/CT for restaging during radioligand therapy, advocating instead for post-treatment SPECT/CT imaging. While both modalities ...

At the 2025 UCSF-UCLA PSMA Conference, Tanya Dorff discusses PSMA-targeted immunotherapy approaches beyond radioligand therapy. She reviews Poseida's P-PSMA-101 CAR T experience, where promising ...

At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...

At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...

At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...

Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...